Highlights
1 patent
About
Powder-based Intra-nasal Products
Nasus Pharma is developing a number of intranasal powder products aimed at assisting patients in several acute emergency situations (such as opioid overdose and anaphylactic shock) based on its microsphere technology. Nasus's portfolio comprises a number of programs including intranasal naloxone, intranasal epinephrine, and a number of preclinical proof-of-concept programs.
Identity
| Name | Nasus Pharma |
|---|---|
| Slug | nasus-pharma |
| Type / kind | startup |
| Crunchbase ID | nasus-pharma-ltd |
| Source _id | agxzfmlsbGlzdHNpdGVyGAsSC05ld19Db21wYW55GICA4NHCsrsIDA |
Status
| Status | active |
|---|---|
| Status reason | Public on NYSE on Aug 2025; |
| Last update | 2026-05-17 |
Location
| HQ country code | IL |
|---|---|
| HQ region/district | Center District |
| HQ city | Tel Aviv-Yafo |
| HQ address | Menachem Begin Road 48, Tel Aviv-Yafo, Israel |
Web & social
| Website | https://nasuspharma.com |
|---|---|
| https://www.linkedin.com/company/66246579 | |
| YouTube | https://www.youtube.com/channel/UCwwBPWMXT6vFkbKFab4-40g |
Classifications
Primary sector Health Tech & Life Sciences
Sub-sectors
Health Tech & Life SciencesPharma & Medical BiotechnologyDrug Delivery
Technologies
Materials & Substances
Target customers
Healthcare & Life SciencesLife SciencesPharmaceuticals
Business models
B2B2C
Tags
drug-deliverynon-invasivemedical-technologiesemergency-responsepharmaceuticalstreatmentsrespiratorybiopharmaceuticalinhalationbacteriamedical-devicespublic-health
Funding
| Total raised | $25.0M |
|---|---|
| Current stage | Public |
| Market cap | $82.9M |
Raw source document
Show full JSON (0 KB)
{
"0": "s",
"1": "l",
"2": "i",
"3": "m",
"4": "p",
"5": "a",
"6": "g",
"7": "e",
"8": "s",
"9": "_",
"10": "i",
"11": "m",
"12": "p",
"13": "o",
"14": "r",
"15": "t"
}